Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Ohio State University Comprehensive Cancer Center
AbbVie
Ohio State University Comprehensive Cancer Center
Daiichi Sankyo
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
University of Alabama at Birmingham
University of Alabama at Birmingham
M.D. Anderson Cancer Center
The First Affiliated Hospital of Xiamen University
Peter MacCallum Cancer Centre, Australia
First Affiliated Hospital of Zhejiang University
Cogent Biosciences, Inc.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Insel Gruppe AG, University Hospital Bern
Prince of Wales Hospital, Shatin, Hong Kong
Therapeutic Advances in Childhood Leukemia Consortium